학술논문
380MO A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
Document Type
Abstract
Author
Source
In Annals of Oncology November 2020 31 Supplement 6:S1389-S1389
Subject
Language
ISSN
0923-7534